Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Research

• Publication date

  2014-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-14-1174PMID 25320006
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.

  2014cited by this paper
• The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

  2014cited by this paper
• WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.

  2014cited by this paper
• BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling

  2014cited by this paper
• Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

  2014cited by this paper
• MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

  2014cited by this paper
• Abstract A48: Therapeutic targeting of colorectal cancer stem cells with BNC101, a functional anti-LGR5 monoclonal antibody.

  2013cited by this paper
• Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching.

  2013influential reference
• AXL induces epithelial to mesenchymal transition and regulates the function of breast cancer stem cells

  2013influential reference
• HER2 and breast cancer stem cells: more than meets the eye.

  2013cited by this paper
• Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts

  2013cited by this paper
• Directed phenotype switching as an effective antimelanoma strategy.

  2013cited by this paper
• Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

  2013influential reference
• An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

  2012cited by this paper
• Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

  2012cited by this paper
• Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)

  2012cited by this paper
• Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer

  2012influential reference
• MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.

  2012cited by this paper
• Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.

  2012cited by this paper
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

  2012cited by this paper
• A landscape of driver mutations in melanoma.

  2012cited by this paper
• A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative.

  2011cited by this paper
• The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report

  2010cited by this paper
• TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

  2010cited by this paper
• Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized.

  2010cited by this paper
• Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.

  2010cited by this paper
• A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

  2010cited by this paper
• The Orphan Tyrosine Kinase Receptor, ROR2, Mediates Wnt5A Signaling in Metastatic Melanoma

  2009cited by this paper
• Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

  2008cited by this paper
• Efficient tumor formation by single human melanoma cells

  2008cited by this paper
• The epithelial-mesenchymal transition generates cells with properties of stem cells.

  2008cited by this paper
• Efficient tumour formation by single human melanoma cells

  2008cited by this paper
• In vivo switching of human melanoma cells between proliferative and invasive states.

  2008cited by this paper
• Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells

  2008cited by this paper
• Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma

  2007cited by this paper
• Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

  2007cited by this paper
• Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.

  2006cited by this paper
• Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

  2005cited by this paper
• Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma.

  2002cited by this paper

• BRAF/MEK inhibitor rechallenge in patients with non-resectable or metastatic BRAF V600-mutated melanoma: a stratified, controlled, retrospective EUMelaReg multicenter study

  2026cites this paper
• miRNA-driven cancer cell plasticity, tolerance and therapy resistance: lessons from melanoma.

  2026cites this paper
• A memory-driven reinforcement learning model of phenotypic adaptation for anticipating therapeutic resistance in prostate cancer

  2025cites this paper
• Evolutionary dynamics of acid resistance in tumors: A mathematical model.

  2025cites this paper
• Environmental transition navigates phenotype switching, affecting the virulence and multidrug-resistant profile of pathogenic Morganella morganii.

  2025cites this paper
• Schwann cells in regeneration and cancer: an epithelial–mesenchymal transition perspective

  2025cites this paper
• Phenotype switching in highly invasive resistant to vemurafenib and cobimetinib melanoma cells

  2025cites this paper
• ATAD2 drives melanoma growth and progression and inhibits ferroptosis

  2025cites this paper
• Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma

  2025cites this paper
• Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers

  2024cites this paper
• Deciphering cellular plasticity in pancreatic cancer for effective treatments

  2024cites this paper
• Uncovering the signaling networks of disseminated glioblastoma cells in vivo with INSIGHT

  2024cites this paper
• Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance

  2024cites this paper
• mTORC2-driven chromatin cGAS mediates chemoresistance through epigenetic reprogramming in colorectal cancer

  2024cites this paper
• Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies

  2024cites this paper
• PKN2 is a dependency of the mesenchymal-like cancer cell state.

  2024cites this paper
• The emergence of multidrug-resistant Proteus vulgaris infection in cage reared Pangasianodon hypophthalmus: molecular characterization and host-pathogen response.

  2024cites this paper
• Translational control of cell plasticity drives 5-FU tolerance

  2024cites this paper
• Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors

  2024cites this paper
• BRAF/MEK inhibitor rechallenge in advanced melanoma patients

  2024cites this paper
• Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

  2023cites this paper
• Investigating bio-remediation capabilities of a constructed wetland through spatial successional study of the sediment microbiome

  2023cites this paper
• Combining Epigenetic and Immunotherapy in Cancer: Molecular Mechanisms

  2023cites this paper
• Canonical Wnt and TGF-β/BMP signaling enhance melanocyte regeneration but suppress invasiveness, migration, and proliferation of melanoma cells

  2023cites this paper
• Overcoming phenotypic switching: targeting protein-protein interactions in cancer

  2023cites this paper
• Connecting the dots: Melanoma cell of origin, tumor cell plasticity, trans-differentiation, and drug resistance.

  2023cites this paper
• Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance

  2023cites this paper
• Quantifying cancer cell plasticity with gene regulatory networks and single-cell dynamics

  2023cites this paper
• The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance

  2023cites this paper
• Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line.

  2023cites this paper
• MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives.

  2023cites this paper
• Single‐cell RNA sequencing of a poorly metastatic melanoma cell line and its subclones with high lung and brain metastasis potential reveals gene expression signature of metastasis with prognostic implication

  2023cites this paper
• Targeting drug‐tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells

  2023cites this paper
• Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance

  2022cites this paper
• Mitochondria in cancer: clean windmills or stressed tinkerers?

  2022cites this paper
• Chemoresistance-Related Stem Cell Signaling in Osteosarcoma and Its Plausible Contribution to Poor Therapeutic Response: A Discussion That Still Matters

  2022cites this paper
• Scales of Cancer Evolution: Selfish Genome or Cooperating Cells?

  2022cites this paper
• Single-Cell Transcriptomic Analysis Reveals the Crosstalk Propensity Between the Tumor Intermediate State and the CD8+ T Exhausted State to be Associated with Clinical Benefits in Melanoma

  2022cites this paper
• Clonality and timing of relapsing colorectal cancer metastasis revealed through whole-genome single-cell sequencing

  2022cites this paper
• Single-cell RNA sequencing reveals the existence of pro-metastatic subpopulation within a parental B16 murine melanoma cell line.

  2022cites this paper
• Selumetinib: a selective MEK1 inhibitor for solid tumor treatment

  2022cites this paper
• The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma

  2022cites this paper
• DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF

  2022cites this paper
• Cancer evolution: Darwin and beyond

  2021cites this paper
• A model for the intrinsic limit of cancer therapy: Duality of treatment-induced cell death and treatment-induced stemness

  2021cites this paper
• Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4

  2021cites this paper
• Changes in Biomechanical Properties of A375 Cells Due to the Silencing of TMSB4X Expression Are Not Directly Correlated with Alterations in Their Stemness Features

  2021cites this paper
• Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer

  2021influential citation
• Luteolin attenuates cancer cell stemness in PTX-resistant oesophageal cancer cells through mediating SOX2 protein stability.

  2021cites this paper
• The genetic and epigenetic basis of distinct melanoma types

  2021cites this paper
• Is resistance to targeted therapy in cancer inevitable?

  2021cites this paper
• Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates anti-tumor immune responses.

  2021cites this paper
• ReviewCancer Stem Cells

  2021cites this paper
• Translation of single-cell transcriptomic analysis of uveal melanomas to clinical oncology.

  2021cites this paper
• Melanoma differentiation trajectories determine sensitivity towards pre-existing CD8+ tumor-infiltrating lymphocytes.

  2021cites this paper
• Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy

  2021influential citation
• CDK7 and MITF repress a transcription program involved in survival and drug tolerance in melanoma

  2021cites this paper
• Melanoma-derived induced pluripotent stem cells

  2021cites this paper
• Syntaphilin downregulation facilitates radioresistance via mediating mitochondria distribution in esophageal squamous cell carcinoma.

  2021cites this paper
• Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

  2021cites this paper
• Cancer Stem Cells—Key Players in Tumor Relapse

  2021cites this paper
• Cancer Hallmarks Define a Continuum of Plastic Cell States between Small Cell Lung Cancer Archetypes

  2021cites this paper
• Group Behavior and Emergence of Cancer Drug Resistance.

  2021cites this paper
• The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma

  2021cites this paper
• Tracking of Melanoma Cell Plasticity by Transcriptional Reporters

  2021cites this paper
• Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies

  2021cites this paper
• Phenotypic Switching of B16F10 Melanoma Cells as a Stress Adaptation Response to Fe3O4/Salicylic Acid Nanoparticle Therapy

  2021cites this paper
• Effects of bidirectional phenotype switching on signal noise in a bacterial community.

  2021cites this paper
• Epithelial‐to‐mesenchymal‐like transition events in melanoma

  2021cites this paper
• Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas

  2021cites this paper
• Rethinking the biology of metastatic melanoma: a holistic approach

  2021cites this paper
• Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?

  2021cites this paper
• The Role of Sphingolipids Metabolism in Cancer Drug Resistance

  2021cites this paper
• RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy

  2021cites this paper
• Canine Oral Melanoma Genomic and Transcriptomic Study Defines Two Molecular Subgroups with Different Therapeutical Targets

  2021cites this paper
• Reconciling Non-Genetic Plasticity with Somatic Evolution in Cancer.

  2021cites this paper
• Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.

  2020cites this paper
• TFIIH kinase CDK7 antagonizes phenotype switching and emergence of drug tolerance in melanoma

  2020cites this paper
• The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions.

  2020cites this paper
• miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma

  2020cites this paper
• Reversal of pre-existing NGFR-driven tumor and immune therapy resistance

  2020cites this paper
• The acidic tumor microenvironment drives a stem-like phenotype in melanoma cells

  2020cites this paper
• Non-genetic mechanisms of therapeutic resistance in cancer

  2020cites this paper
• Principles of seed banks and the emergence of complexity from dormancy

  2020cites this paper
• Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors

  2020cites this paper
• NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma

  2020cites this paper
• Genomic profiling of a dedifferentiated mucosal melanoma following exposure to immunotherapy

  2020cites this paper
• The MNK1/2-eIF4E axis drives melanoma plasticity, progression, and resistance to immunotherapy

  2020cites this paper
• YAP and β-catenin Co-operate to Drive Oncogenesis in Basal Breast Cancer

  2020cites this paper
• STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway

  2020cites this paper
• Knockout of ACTB and ACTG1 with CRISPR/Cas9(D10A) Technique Shows that Non-Muscle β and γ Actin Are Not Equal in Relation to Human Melanoma Cells’ Motility and Focal Adhesion Formation

  2020cites this paper
• MEK inhibitor resistance mechanisms and recent developments in combination trials.

  2020cites this paper
• Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum

  2020cites this paper
• Targeted chemotherapy overcomes drug resistance in melanoma

  2020cites this paper
• Cellular Reprogramming—A Model for Melanoma Cellular Plasticity

  2020cites this paper
• NRF2‐dependent stress defense in tumor antioxidant control and immune evasion

  2020cites this paper
• Antimigratory Activity of Brazilin-Containing Fraction from Caesalpinia sappan L. on MDAMB-231 Cells

  2020cites this paper
• Phenotypic Heterogeneity in Tumor Progression, and Its Possible Role in the Onset of Cancer

  2020cites this paper
• Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors

  2020cites this paper
• WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion

  2020cites this paper